D
iabetes is associated with severe atherosclerosis and cardiovascular diseases that account for a high mobility and mortality in industrialized countries. 1 It is therefore very important for us to understand the mechanisms of how the diseases occur. Advanced glycosylation end products (AGEs) (long-term products of the Maillard reaction) have been shown to play a causative role in diabetic vasculopathy and atherosclerosis. 2, 3 In diabetic atherosclerotic lesions, not only the deposition of AGEs but also the colocalization of AGEs antigen and AGEs receptors (scavenger receptor A [SR-A], receptor for AGEs [RAGE] ) were found. 2, 3 Additionally, accumulating evidences have suggested that dendritic cells (DCs) also play a crucial role in atherosclerosis 4 by activating T-cell in atherosclerosis. 5 Proinflammatory factors can promote maturation of DCs corresponding to a switch from a phagocytic stage to a stage of strong T cell-stimulatory capacity. The interactive roles of AGEs and DCs remain unknown now. We therefore examined the effect of advanced glycosylation end-bovine serum albumin (AGE-BSA) on DCs maturation, cytokine secretion, and SR-A and RAGE expression.
Methods
The informed consent was obtained from all volunteers and the study protocol was approved by our institutional ethical committee.
Materials

Human CD14
ϩ immunomagnetic microbeads were obtained from Miltenyi Biotech GmbH (Bergisch-Gladbach, Germany), recombinant human granulocyte-macrophage colony-stimulating factor (CSF) (rhGM-CSF), recombinant human IL-4 (rhIL-4), enzymelinked immunosorbent (ELISA) kit for IL-2, IL-10, IL-12, and interferon-␥ (IFN-␥) from R&D, Histopaque-1077 from Sigma, total RNA extraction miniprep system from Viogen-BioTEK, human T-cell recovery immunocolumn kit from Cedarlane Laboratories Ltd (Ontario, Canada), and SR-A (goat anti-human polyclonal antibody) from Santa Cruz Biotechnology. A goat anti-human RAGE polyclonal antibody (Chemicon; Cat# AB5484) was used in the present study for Western blotting. The anti-RAGE neutralizing antibody was a kind gift from the Department of Immunology, Southern Medical University (Guangzhou, China). CD1a-fluorescein isothiocyanate (FITC), CD40-FITC, CD80-FITC, CD83-FITC, CD86-FITC, HLA-DR-FITC, mouse anti-human antibodies from BD Pharmingen, rabbit anti-Phospho-p38 MAP kinase antibody, rabbit anti-phospho Erk IgG, and rabbit anti-phospho-Jnk IgG from Cell Signaling Technology.
Preparation of AGE-BSA
AGE-BSA was prepared as previously described. 6 -8 BSA was added into 10 mmol/L phosphate-buffered saline (PBS) (pH 7.4, concentration of 5 g/L), incubated with 50 mmol/L D-glucose in 5% CO 2 /95% air at 37°C for 12 weeks. Unincorporated glucose was removed by dialysis overnight against PBS. AGE-BSA specific fluorescence determinations were performed by measuring emission at 440 nm on excitation at 370 nm using a fluorescence spectrophotometer (Hitachi, Japan). The fluorescence intensity of AGE-BSA was Ϸ60-times higher than it of BSA. AGE-BSA content was estimated by fluorescence intensity at a protein concentration of 1 mg/mL. AGE-BSA was stored at Ϫ70°C until use.
Preparation of Human Monocytes and Monocyte-Derived DCs
DCs were prepared as previously described. 9, 10 Peripheral blood mononuclear cells were obtained from healthy volunteers. Briefly, blood was diluted 1:2 in PBS layered over Histopaque 1077 and centrifuged for 30 minutes at 2000 rpm at room temperature. The interface was recovered and washed 3 times in PBS. CD14 ϩ peripheral blood mononuclear cells were purified by using CD14 ϩ immunomagnetic micro beads (Ͼ98%) and incubated in RPMI-1640 medium supplemented with GM-CSF (100 ng/mL) and IL-4 (50 ng/mL) in 6-well tissue culture plates at 37°C and an atmosphere of 5% CO 2 . The medium was replaced every 2 days. After 8 days, DCs were stimulated by AGEs.
Semi-Quantitative Reverse-Transcription PCR Analysis
Total cellular RNA was extracted from cells using total RNA extraction miniprep system according to the manufacture's instruction. Oligo (dT) 18 were used for cDNA preparation. For detection of SR-A, the primers were as follows (365 bp): forward, 5Ј-CCAGGGACATGGGAATGCAA-3Ј; reverse, 5Ј-CCAGTGGG-ACCTCGATCTCC-3Ј. Primers for RAGE were as follows (240bp): forward, 5Ј-AAGCCCCTGGTGCCTAATGAG-3Ј; reverse, 5Ј-CACCAATTGGACCTCCT-CCA-3Ј. Primers for endogenous control of GAPDH were as follows (835 bp): forward, 5Ј-TTCACC-ACCATGGAGAAGG-3Ј; reverse, 5Ј-AGGGGTCTACATGGCA-ACTG-3Ј. PCR was performed as follows: 95°C for 1 minute followed by 30 cycles at 94°C for 1 minute, 60°C for 1 minute, 72°C for 2 minutes, followed by a final step at 72°C for 8 minutes. PCR products were separated by electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining. Relative intensities of the bands of interest were analyzed with TotalLab V1.11 software (Nonlinear Dynamics). The gene expression level was determined semi-quantitatively by calculating the ratio from the target gene in relation to internal standard.
Western Blot Analysis
Cells were lysed in RIPA lysis buffer with PMSF at 4°C with sonication for 30 minutes. The lysates were centrifuged at 15 000g for 30 minutes. Loading buffer was added to each volume and boiled for 10 minutes. Samples were resolved on 12% SDS-PAGE and electro-transferred onto a nitro-cellulose membrane. The membrane was blocked with 5% nonfat milk. Blots were incubated with goat anti-human SR-A IgG, goat anti-human RAGE IgG, rabbit antiphospho Erk IgG, rabbit anti-phospho-p38 MAPK IgG, rabbit anti-phospho Jnk IgG, each at a dilution of 1:1000 for 12 hours at 4°C. The blots were washed in Tris-buffered saline containing 0.2% Tween 20 and exposed to HRP-conjugated anti-goat IgG or antirabbit secondary antibody (1:1500) for 60 minutes, respectively, and the membranes were detected with the SuperSignal West Pico chemiluminescence system (Pierce Biotechnology). Relative intensities of protein bands were analyzed by TotalLab software.
Flow Cytometric Measurement
DCs were exposed to 0 g/mL AGE-BSA, 200 g/mL BSA, or 200 g/mL AGE-BSA for 24 hours. Cells (1ϫ10 6 ) were harvested and washed, then incubated with FITC-conjugated mAbs (CD1a-FITC, CD40-FITC, CD80-FITC, CD83-FITC, CD86-FITC, HLA-DR-FITC) for 30 minutes at 4°C. Then, the cells were analyzed using flow cytometer (Becton Dickinson). Cells stained with the appropriate isotype-matched Ig were used as negative controls.
Quantification of Cytokine Production
The supernatants of DCs were harvested and stored at Ϫ70°C until assay. The cytokine concentration of IL-2, IL-10, IL-12, and IFN-␥ were analyzed using ELISA kits, according to the manufacturer's instruction.
Mixed Lymphocyte Reactions
For the mixed lymphocyte reaction (MLR), T lymphocytes were isolated from peripheral blood by human T cell recovery immunocolumn kit. 
Statistical Analysis
All data were expressed as meanϮSEM and statistically analyzed by 1-way ANOVA. A value of PϽ0.05 was considered statistically significant.
Results
Dendritic Cells Morphology
The CD14 microbeads sorted monocytes were symmetrical and the purity was Ͼ98%. Twenty-four hours later, the most cells formed the different clones, which became large; after 96 hours, the dendrites were clearly observed (data not shown).
Concentration-Dependent Upregulation of SR-A Expression in DCs by AGE-BSA
DCs were exposed to BSA (200 g/mL) or AGE-BSA at various concentrations (0, 50, 100, 200, and 300 g/mL) for 24 hours. SR-A expression of DCs at mRNA and protein level after various treatments were shown in Figure 1A and 1B, respectively. SR-A at mRNA and protein levels increased in a concentration-dependent manner post AGEs treatment and peaked at a concentration of 200 g/mL, whereas SR-A expression remained unchanged in BSA-treated DCs.
Time-Dependent Upregulation of SR-A Expression in DCs by AGE-BSA
respectively. RAGE expressions at mRNA and protein levels were significantly increased after AGE-BSA treatment and remained unchanged in BSA-treated DCs in comparison with untreated DCs.
AGE-BSA Stimulation Activates MAPK Pathways in DCs
Phosphorylation of MAP kinase family proteins including Erk, Jnk, and p38 was measured to gain insight into the changes of AGE-BSA-induced signaling pathways in DCs. DCs were stimulated with AGE-BSA (200 g/mL) for 0, 10, 20, 30, and 40 minutes. Phosphorylation of Erk, Jnk, p38 MAPK was assayed by Western-blot. Increases in the phosphorylation levels of Erk, Jnk, and P38 were visible at 10 minutes, peaked at 20 minutes, and declined thereafter (Figure 2A through 2C) .
Role for MAPK Pathways in the AGE-BSA-Induced Upregulation of the SR-A and RAGE
DCs were exposed to AGE-BSA (200 g/mL), AGE-BSA (200 g/mL) plus Erk inhibitor PD98059 (50mol/L), 11 AGE-BSA (200 g/mL) plus Jnk inhibitor SP600125 (50 mol/L), 12 and AGE-BSA (200 g/mL) plus p38 MAPK inhibitor SB203580 (10 mol/L). 11 DCs were pretreated with respective inhibitors for 1 hour, followed by stimulation with AGE-BSA for an additional 23 hours, and the expressions of SR-A and RAGE were measured. The increase in SR-A and RAGE expressions after AGE-BSA was significantly inhibited by cotreatment with Jnk inhibitor SP600125, but not by Erk inhibitor PD98059 and p38 MAPK inhibitor SB203580 ( Figure 2D and 2E).
AGE-BSA-Induced Upregulation of Surface Molecules in DCs
Fluorescence-activated cell sorter (FACS) analysis showed that the expressions of CD1a, CD40, CD80, CD83, CD86, and HLA-DR in AGE-BSA-treated DCs were increased significantly compared with the BSA and untreated DCs (Figure 3) . It indicated that AGE-BSA could promote the maturation of DCs.
AGE-BSA-Induced Cytokine Secretions by DCs
DCs were exposed to BSA (200 g/mL) or AGE-BSA (200 g/mL). After AGE-BSA treatment, secretion of IFN-␥ ( Figure  4A ), T H 1 cytokine IL-12 ( Figure 4B ), and T H 2 cytokine IL-10 ( Figure 4C ) were all increased compared with BSA treated DCs and untreated control DCs. However, IL-2 levels remained unchanged after AGE-BSA treatment ( Figure 4D ).
AGE-BSA Enhances the Capacity of DCs to Stimulate T Cells
Compared with untreated control DCs, AGE-BSA-treated DCs increased the proliferation of T cells ( Figure 5A ). Simultaneously, AGE-BSA-treated DCs increased the secretion of IL-2 by T cells by Ͼ3-fold at 1:5 and 1:10 DCs/T cells ratio ( Figure 5D and 5C) and by Ͼ2-fold at 1:20 DCs/T cells ratio ( Figure 5B ).
Role of Anti-RAGE Neutralizing Antibody in the AGE-BSA-Induced Upregulation of CD83 and Secretion of IL-12
DCs were pretreated with 50 g/mL of anti-RAGE neutralizing antibody for 1 hour followed by 200 g/mL of AGE-BSA for 23 hours. Untreated DCs were as control. Compared with AGE-BSA-treated DCs, anti-RAGE neutralizing antibody inhibited partly upregulation of CD83 and secretion of IL-12 ( Figure 6A and 6C) . 
Role of Jnk Inhibitor in the AGE-BSA-Induced Upregulation of CD83 and Secretion of IL-12
DCs were pretreated with Jnk inhibitor SP600125 (50mol/L) for 1 hour followed by 200 g/mL of AGE-BSA for 23 hours. Untreated DCs were as control. Compared with AGE-BSA-treated DCs, SP600125 inhibited upregulation of CD83 and secretion of IL-12 ( Figure 6B and 6D) .
Discussion
In the present study, we found that AGE-BSA induced the maturation of DCs characterized by upregulation of CD1a, CD40, CD80, CD83, CD86, and MHC class II. In parallel, secretion of proinflammatory or Th1-type cytokines, like IFN-␥ and IL-12, and also the Th2-type cytokine IL-10, was significantly increased after AGE-BSA treatment. In addition, AGE-BSA enhanced the capacity of DCs to stimulate T-cell proliferation in allogenic MLRs. Moreover, AGE-BSA enhanced the expressions of SR-A and RAGE, and the inhibition of the receptor expression abolished AGE-BSAinduced DCs maturation and cytokine secretion. Furthermore, inhibition of Jnk suppressed upregulation of not only SR-A and RAGE expressions on DCs but also DCs maturation and cytokine secretion induced by AGE-BSA. Therefore, AGE-BSA could be involved in atherosclerosis processes through inducing DCs maturation and increasing SR-A and RAGE expressions, which were mediated by Jnk signal pathway. To our knowledge, this is the first study showing these important effects of AGEs on DCs.
Previous immunohistochemical and ultrastructural studies have shown increased DCs in atherosclerotic arteries. [13] [14] [15] Various antigens, such as oxidized low-density lipoprotein (ox-LDL), 16 heat shock protein (HSP), 17 and nicotine, 11 could activate DCs immunity. The present study showed for the first time that AGEs could also induce the maturation of DCs. Compared with immature DCs, maturation of DCs involves the downregulation of endocytotic activity and the upregulation of adhesion molecules, costimulatory molecules, and antigen-presenting molecules, including the class I and class II of MHC proteins and CD1 molecules. Coexpression of the adhesion and costimulatory and antigen-presenting molecules enable DCs to form contacts with and activate T cells. In our study, we found AGE-BSA enhanced the expressions of CD1a, CD40, CD80, CD83, CD86, and HLA-DR. Therefore, AGE-BSA could also induce the maturation of DCs like ox-LDL. Moreover, we found that AGE-BSA-treated DCs were able to secrete more IL-12 than IL-10. This finding suggested that AGE-treated DCs might be more potent in priming naive T cells for type-1 cytokine response and cell-mediated immunity. Secretion of IFN-␥ from DCs was also increased by AGE-BSA. Because IL-12 and IFN-␥ released by activated DCs contributed to the formation of atherosclerotic lesions and plaque destabilization, 18, 19 our findings suggest that AGEs might promote the atherosclerosis by enhancing the maturation and immunity of DCs. Quite recently, Price et al 20 reported that AGEs prohibited the maturation of DCs and AGE-treated DCs had a loss in T-cell stimulation capacity, which is different from our present study. Although we do not know the reason for the discrepancy at present, there might be several possibilities. At first, Price et al used CD14
Ϫ DCs whereas we used CD14 ϩ DCs. The difference in cell types might cause different results. Whether CD14
Ϫ and CD14 ϩ DCs function differently in atherosclerosis remains unclear. Second, Price et al used AGE-corticotropin (ACTH) angiotensin, whereas we used AGE-BSA as an antigen. The responses of DCs to the 2 antigens might be divergent.
It was found that IL-2 further activated the T cells and might potentially enhance atherogenesis. 21 In this study, we did not find a significant increase of IL-2 in DCs by AGE-BSA treatment; however, in the presence of T cells (MLRs), AGE-BSA-treated DCs strongly stimulated the proliferation of T cells and the secretion of IL-2 in proportion to DCs/T ratio. Therefore, IL-2 was mainly originated from T cells and AGEs could further magnify the effects of IL-2 in atherosclerosis by activating the T cells and increasing IL-2 secretion via DCs.
AGEs have currently been shown to play a causative role in diabetic vasculopathy, including atherosclerosis as well as microangiopathy. 12 Previous mechanism studies in this field were mainly focused on endothelial cells, monocyte cells, and smooth muscle cells. 22 Results of the present study show that one of the mechanisms in which AGEs promote atherogenesis is achieved by their effects on DCs. SR-A is one of the receptors of AGEs and responsible for mediating cholesterol accumulation by macrophages during the development of atherosclerotic lesions. A recent study has shown that the atherosclerotic lesions were reduced by more than 70% in SR-A knockout mice. 23 In accordance with this finding, we found that AGEs could enhance the expression of SR-A in DCs in dose and time dependent manners, supporting the role of AGEs on atherogenesis.
RAGE is the specific receptor of AGEs. RAGE is expressed at low levels in normal tissues and vasculature. In diabetic vasculature, cells expressing high levels of RAGE are often proximal to areas in which AGEs are abundant, RAGE expression is increased in endothelium, smooth muscle cells, and infiltrating mononuclear phagocytes in diabetic vasculature. 24 In this study we found AGE-BSA could significantly enhance the expression of RAGE and activate the MAPK family (Erk, Jnk, P38) in DCs. Previous studies showed that Erk and Jnk inhibition protected various cells from apoptosis and both Erk and p38 MAPK could upregulate surface molecules. 11, 25 The Jnk inhibitor, but not Erk and p38 inhibitors, significantly attenuated the expression of RAGE and SR-A. It suggested the possible involvement of Jnk pathway in AGE-BSA-induced upregulation of SR-A and RAGE expressions. In addition, we also observed that pretreatment of DCs with an anti-RAGE neutralizing antibody or a Jnk inhibitor partly inhibited AGE-induced upregulation of CD83 and secretion of IL-12. It suggests that AGE-induced maturation of DCs is at least in part through RAGE and Jnk signal pathway. Combining with the result that Jnk inhibitor attenuated the induction of RAGE and SR-A on DCs, we suggest that Jnk inhibitor decreased the amount of AGEs into DCs, resulting in the decrease of the antigen in DCs and then the lesser DC maturation and cytokine secretion. However, as we tried to test whether SR-A is also involved in the effects of AGE on DCs by using 2 SR-A inhibitors (namely genistein and name polyinosinic acid), it was found that the treatment with either of them affected maturation of DCs. Polyinosinic acid could induce the maturation of DCs and Genistein could inhibit directly the maturation of DCs because it was an inhibitor of tyrosine protein kinase. These results failed to provide direct evidence showing whether SR-A is involved in the receptor induction and DC maturation by AGE. However, because the Jnk inhibitor that suppressed both RAGE and SR-A expressions on DCs had a stronger inhibitory effect on DCs maturation than an anti-RAGE neutralizing antibody, which only partially inhibited DCs maturation, it may be suggested that AGE-BSA entered DCs and induced DC maturation through both RAGE and SR-A. The sequelae of this increased expression of RAGE and SRA by AGEs might modulate inflammatory response by increasing the expression of oxidant radical formation, proinflammatory cytokines, growth factors, and vascular adhesion molecules, therefore promoting atherosclerotic plaque formation, endothelial dysfunction, and diabetic vasculopathy. 26, 27 Our results suggest that AGEs bind to DCs through SR-A and RAGE receptors, induce the maturation of DCs, and activate antigen-specific T cells, as well as initiate immune reaction and promote atherosclerosis. Our recent study showed that PPAR-␥ agonist ciglitazone could inhibit the ox-LDL-induced maturation of DCs. 28 It is, therefore, reasonable to speculate that AGEs inhibitors might be also candidates for atherosclerosis therapy by inhibiting DCs maturation and immunity.
In conclusion, AGEs could induce the maturation of DCs and enhance immunity of DCs through increasing the expressions of SR-A and RAGE, which were mediated by Jnk pathway. The present study suggests a possibility of the application of anti-RAGE antibody and Jnk inhibitors for atherosclerosis therapy.
